AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

Vandana Singh
1 min read
0
In this article:

  • AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis.

  • Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.

  • Excess cystine damages cells and often forms crystals that can build up and cause many organs and tissue problems.

  • AVR-RD-04 genetically modifies patients' hematopoietic stem cells (HSC) to express a functional version of cystinosin, the protein deficient in cystinosis patients.

  • Related: After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data.

  • Preliminary data suggest that post gene therapy, functional cystinosin has been produced throughout the body, as evidenced by clinical measures in multiple tissues.

  • No adverse events related to the drug product have been reported.

  • Following discontinuation of cysteamine, average handgrip strength remained stable up to 27 months after dosing.

  • The first three patients observed a decline in cystine crystals in the skin and gastrointestinal mucosa biopsies.

  • Safety data from the five patients dosed indicate no AEs related to the drug product. All AEs were related to myeloablative conditioning, stem cell mobilization, underlying disease, or pre-existing conditions.

  • The company expects to initiate an AVROBIO-sponsored trial in 2023 in the U.S.

  • AVROBIO's current plan involves a two-part strategy, beginning in a pre-renal transplant population followed by a post-renal transplant population.

  • Price Action: AVRO shares are up 3.26% at $0.81 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories